Citigroup’s Rhythm Pharmaceuticals RYTM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.07M | Sell |
12,336
-384
| -3% | -$37.3K | ﹤0.01% | 3073 |
|
|
2025
Q4 | $1.36M | Sell |
12,720
-360
| -3% | -$38.2K | ﹤0.01% | 2935 |
|
|
2025
Q3 | $1.32M | Sell |
13,080
-21,244
| -62% | -$1.97M | ﹤0.01% | 2982 |
|
|
2025
Q2 | $2.17M | Sell |
34,324
-51,882
| -60% | -$3.18M | ﹤0.01% | 2570 |
|
|
2025
Q1 | $4.57M | Buy |
86,206
+16,429
| +24% | +$911K | ﹤0.01% | 1984 |
|
|
2024
Q4 | $3.91M | Buy |
69,777
+28,580
| +69% | +$1.58M | ﹤0.01% | 2213 |
|
|
2024
Q3 | $2.16M | Buy |
41,197
+21,205
| +106% | +$1.02M | ﹤0.01% | 2597 |
|
|
2024
Q2 | $821K | Sell |
19,992
-170,528
| -90% | -$6.81M | ﹤0.01% | 3052 |
|
|
2024
Q1 | $8.26M | Buy |
190,520
+136,220
| +251% | +$5.96M | 0.01% | 1358 |
|
|
2023
Q4 | $2.5M | Sell |
54,300
-14,844
| -21% | -$468K | ﹤0.01% | 2056 |
|
|
2023
Q3 | $1.59M | Sell |
69,144
-18,921
| -21% | -$424K | ﹤0.01% | 2158 |
|
|
2023
Q2 | $1.45M | Sell |
88,065
-251,890
| -74% | -$4.55M | ﹤0.01% | 2522 |
|
|
2023
Q1 | $6.06M | Buy |
339,955
+64,394
| +23% | +$1.62M | ﹤0.01% | 1397 |
|
|
2022
Q4 | $8.02M | Buy |
275,561
+3,374
| +1% | +$86.7K | 0.01% | 1237 |
|
|
2022
Q3 | $6.67M | Buy |
272,187
+269,921
| +11,912% | +$5.02M | ﹤0.01% | 1379 |
|
|
2022
Q2 | $9K | Sell |
2,266
-2,266
| -50% | -$12.4K | ﹤0.01% | 5411 |
|
|
2022
Q1 | $52K | Sell |
4,532
-91,485
| -95% | -$803K | ﹤0.01% | 4716 |
|
|
2021
Q4 | $958K | Buy |
96,017
+36,291
| +61% | +$408K | ﹤0.01% | 3308 |
|
|
2021
Q3 | $780K | Sell |
59,726
-72,173
| -55% | -$1.1M | ﹤0.01% | 3280 |
|
|
2021
Q2 | $2.58M | Sell |
131,899
-20,529
| -13% | -$426K | ﹤0.01% | 2463 |
|
|
2021
Q1 | $3.24M | Buy |
152,428
+143,603
| +1,627% | +$4.16M | ﹤0.01% | 2137 |
|
|
2020
Q4 | $262K | Buy |
8,825
+1,429
| +19% | +$36.3K | ﹤0.01% | 4777 |
|
|
2020
Q3 | $160K | Sell |
7,396
-15,938
| -68% | -$365K | ﹤0.01% | 4774 |
|
|
2020
Q2 | $520K | Buy |
23,334
+3,299
| +16% | +$64.3K | ﹤0.01% | 4224 |
|
|
2020
Q1 | $305K | Buy |
20,035
+5,585
| +39% | +$100K | ﹤0.01% | 4345 |
|
|
2019
Q4 | $332K | Sell |
14,450
-1,587
| -10% | -$35.3K | ﹤0.01% | 4766 |
|
|
2019
Q3 | $347K | Sell |
16,037
-8,809
| -35% | -$189K | ﹤0.01% | 4679 |
|
|
2019
Q2 | $547K | Buy |
24,846
+21,550
| +654% | +$544K | ﹤0.01% | 4329 |
|
|
2019
Q1 | $91K | Sell |
3,296
-64,607
| -95% | -$1.86M | ﹤0.01% | 5841 |
|
|
2018
Q4 | $1.82M | Buy |
67,903
+40,469
| +148% | +$1.12M | ﹤0.01% | 2758 |
|
|
2018
Q3 | $801K | Buy |
27,434
+25,678
| +1,462% | +$811K | ﹤0.01% | 3749 |
|
|
2018
Q2 | $55K | Buy |
1,756
+715
| +69% | +$19.6K | ﹤0.01% | 6219 |
|
|
2018
Q1 | $21K | Buy |
1,041
+113
| +12% | +$3K | ﹤0.01% | 6721 |
|
|
2017
Q4 | $27K | Buy |
+928
| New | +$24.5K | ﹤0.01% | 6572 |
|
Other funds holding RYTM
RCM
BBA
VPM
VCM
PA
Citigroup's RYTM Position: Q1 2026 in Review
Citigroup reduced its Rhythm Pharmaceuticals (RYTM) stake by 3% in Q1 2026, selling an estimated $37.3K and leaving 12,336 shares worth $1.07M. The position accounts for ﹤0.01% of the portfolio, ranked #3073.
Citigroup first reported a position in RYTM in Q4 2017 and has held it in 34 quarters since. The position peaked at $8.26M in Q1 2024. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.
- Citigroup held 12,336 shares of Rhythm Pharmaceuticals worth $1.07M as of Q1 2026.
- Citigroup sold 384 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $37.3K.
- Rhythm Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3073 holding.
- Citigroup first reported a position in Rhythm Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
- Citigroup's Rhythm Pharmaceuticals position peaked at $8.26M in Q1 2024.
- 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.